Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3940
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Ergocalciferol (Capsule)
|
| dailymed-instance:dosage |
Vitamin D Resistant Rickets:: 12,000 to 500,000 USP units daily.<br/>Hypoparathyroidism:: 50,000 to 200,000 USP units daily concomitantly with calcium lactate 4 g, six
times per day.DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION.Calcium intake should be adequate. Blood calcium and phosphorous
determinations must be made every 2 weeks or more frequently if necessary.
X-rays of the bones should be taken every month until condition is corrected and
stabilized.
|
| dailymed-instance:descripti... |
ERGOCALCIFEROL CAPSULES, USP, is a synthetic calcium regulator for oral administration.Ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and
slightly soluble in vegetable oils. It is affected by air and by light. Ergosterol or provitamin Dis found in plants and yeast and has no antirachitic activity.There are more than 10
substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic
activity.One USP Unit of vitamin Dis equivalent to one International Unit (IU), and 1
mcg of vitamin Dis equal to 40 IU.Each softgel, for oral administration,
contains Ergocalciferol, USP 1.25 mg (equivalent to 50,000 USP units of Vitamin D), in an edible
vegetable oil.Ergocalciferol, also called vitamin D, is
9, 10-secoergosta-5,7,10(19),22-tetraen-3-ol,(3��,5Z,7E,22E)-; (CHO)
with a molecular weight of 396.65, and has the following structural formula:
|
| dailymed-instance:clinicalP... |
The in vivo synthesis of the major biologically
active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol
takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys
(to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and
phosphorous by the small intestine, thus elevating serum calcium and phosphate levels sufficiently
to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone
and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal
tubules.There is a time lag of 10 to 24 hours between the administration of vitamin D and the initiation of
its action in the body due to the necessity of synthesis of the active metabolites in the liver and
kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:supply |
Each green, oval softgel is imprinted with PA140 and contains
1.25 mg (50,000 USP units vitamin D) of ergocalciferol, USP, and is available in bottles of
100 or 1000 Softgels. Store at 25��C (77��F); excursions permitted to 15��- 30��C (59��- 86��F) [See USP Controlled Room Temperature.] Protect from light and moisture. Dispense in a tight, light-resistant container as
defined in the USP. Manufactured byBanner Pharmacaps, Inc.4125 Premier DriveHigh Point, NC27265
c/n
|
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:possibleD... | |
| dailymed-instance:precautio... |
General:<br/>Drug Interactions:<br/>Carcinogenesis, Mutagenesis, Impairment of Fertility:<br/>Nursing Mothers:<br/>Pediatric Use:<br/>Geriatric Use: Clinical studies of Ergocalciferol capsules, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. A few published reports have suggested that the absorption of orally administered vitamin D may be attenuated in elderly compared to younger, individuals. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
|
| dailymed-instance:overdosag... |
The effects of administered vitamin D can persist for two or more months after cessation
of treatment.
|
| dailymed-instance:genericMe... |
Ergocalciferol
|
| dailymed-instance:fullName |
Ergocalciferol (Capsule)
|
| dailymed-instance:adverseRe... |
Renal:: Impairment of renal function with polyuria, nocturia, polydipsia,
hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized
vascular calcification, or irreversible renal insufficiency which may result
in death.<br/>CNS: Mental retardation.:<br/>Soft Tissues:: Widespread calcification of the soft tissues, including the heart,
blood vessels, renal tubules, and lungs.<br/>Skeletal:: Bone demineralization (osteoporosis) in adults occurs concomitantly.Decline in the average rate of linear growth and increased mineralization
of bones in infants and children (dwarfism), vague aches, stiffness, and weakness.<br/>Gastrointestinal:: Nausea, anorexia, constipation.<br/>Metabolic:: Mild acidosis, anemia, weight loss.
|
| dailymed-instance:warning |
Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic
hypercalcemia. In these cases vitamin D must be strictly restricted.Keep out of the reach of
children.
|
| dailymed-instance:indicatio... |
Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory
rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Ergocalciferol
|